MedTrace Logo

Antiangiogenic Effects of BCG on Urinary Concentration of Angiogenic Factors

NCT00216814 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2008-04-22

No results posted yet for this study

Summary

To determine if there is an association between basic fibroblast growth factor,vascular endothelial growth factor, and interleukin levels and a patients response to BCG treatment ( as standard treatment)in the urine of patients with superficial TCC. To determine if the levels of these angiogenic factors can predict response to BCG, disease recurrence, progression risk factors.

Conditions

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Jonathan Izawa, MD, FRCSC · LHRI

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-10-31
Completion
2007-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00216814 on ClinicalTrials.gov